To assess immunological assessment of cytokines and other soluble immune biomarkers in CHB subjects not currently on nucleos (t)ide analog (NA) therapy (HBV DNA+) and compare these profiles to NA-suppressed (HBV DNA-) CHB subjects receiving a single dose of AB-729
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Imdusiran (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
Most Recent Events
- 22 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022